GLP-1 Agonists Weight Loss Drugs Market: A New Era in Slimming Solutions

 The global GLP-1 agonist weight loss drugs market was valued at USD 13.84 billion in 2024 and is projected to reach USD 48.84 billion by 2030, growing at a CAGR of 18.54% from 2025 to 2030. This rapid growth is driven by rising obesity rates, growing health awareness, and the proven clinical efficacy of drugs such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound). Pharmaceutical innovations, favorable regulatory approvals, and expanding insurance coverage further support the adoption of these drugs. Additionally, celebrity endorsements and social media influence have increased consumer interest, expanding the market beyond diabetic patients to a broader population seeking weight management solutions.

Obesity continues to be a major global health concern. In 2022, 2.5 billion adults were overweight, including 890 million with obesity, while 37 million children under five were overweight. Poor diet, physical inactivity, and obesogenic environments are key contributors, though obesity is preventable through healthy eating, regular exercise, and lifestyle interventions. The World Health Organization (WHO) emphasizes global action to address obesity, including regulations on food marketing and targeted health interventions.

Global obesity prevalence varies widely, highlighting key market opportunities for GLP-1 agonist drugs. Countries with the highest rates, such as the United States (40.2%), Kuwait (43.75%), and Mexico (36.9%), represent significant growth potential. Gender-specific trends, such as South Africa’s 41.3% female obesity versus 15.3% male, indicate targeted demand for treatments. Conversely, lower rates in Japan (4.6%) and India (5.2%) suggest slower growth in these regions. In Europe, prevalence ranges from 10.4% in Italy to 20.1% in the UK, while in Asia, countries like South Korea report higher male obesity (36.3%) than female (27.6%), shaping regional demand for GLP-1 therapies.

In July 2024, China launched a public awareness campaign addressing obesity, noting that half of its adult population is overweight or obese. Spearheaded by the National Health Commission, the campaign emphasizes balanced diets, physical activity, quality sleep, and family support. With obesity closely linked to chronic diseases like cardiovascular conditions and diabetes, demand for effective pharmacological interventions, including GLP-1 agonists, is expected to grow. Government initiatives, such as "15-minute fitness circles" and updated dietary guidelines, further promote weight management, positioning GLP-1 drugs as complementary to lifestyle interventions.

Order a free sample PDF of the GLP-1 Agonists Weight Loss Drugs Market Intelligence Study, published by Grand View Research.

Key Market Trends & Insights

• Regional Dominance: North America led the GLP-1 agonists weight loss drugs market in 2024 with a revenue share of 75.50%. High obesity prevalence, coupled with increasing accessibility to GLP-1 drugs such as semaglutide (Wegovy), liraglutide (Saxenda), and tirzepatide (Zepbound), drives demand. Both parenteral and oral formulations are widely available through retail and hospital pharmacies.
• Drug Segment: Semaglutide (Wegovy) held the largest market share at 60.70% in 2024. Its growth is fueled by proven weight reduction efficacy, metabolic benefits, regulatory approvals, insurance coverage, and physician adoption. Rising global obesity and strong clinical trial outcomes further boost demand for semaglutide-based treatments.
• Route of Administration: Parenteral drugs dominated in 2024 with a 92.7% revenue share. Injectable formulations like semaglutide and tirzepatide provide high efficacy and bioavailability. Once-weekly dosing, auto-injector technology, and strong patient adherence drive this segment’s growth, supported by regulatory approvals and insurance coverage.
• Distribution Channel: Retail pharmacies accounted for the largest share at 55.46% in 2024. Growing consumer demand for accessible weight loss medications makes retail pharmacies a key channel. Expanded pharmacy services, including patient consultations, education, and home delivery, further enhance adoption of GLP-1 agonists.

Market Size & Forecast

• 2024 Market Size: USD 13.84 Billion
• 2030 Projected Market Size: USD 48.84 Billion
• CAGR (2025-2030): 18.54%
• North America: Largest market in 2024

Key Companies & Market Share Insights

Major players in the GLP-1 agonist weight loss drugs market include Novo Nordisk (Semaglutide), Eli Lilly (Tirzepatide), and other pharmaceutical leaders. These companies are focusing on increasing access to oral formulations, expanding distribution through hospitals and retail pharmacies, and investing in research and development to maintain competitive advantages.

Emerging companies are exploring personalized weight loss therapies tailored to individual patient needs. Novel delivery mechanisms, such as sublingual tablets and extended-release formulations, aim to offer convenient options, addressing unmet medical needs in markets with lower treatment access or where injectable therapies face adoption challenges.

Key Players

• Eli Lilly and Company
• Pfizer Inc.
• Novo Nordisk A/S
• Viking Therapeutics
• Structure Therapeutics

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The GLP-1 agonists weight loss drugs market is poised for significant growth, driven by rising global obesity rates, proven clinical efficacy, and increasing health awareness. North America leads the market, supported by high prevalence and strong infrastructure, while emerging markets such as China present substantial growth opportunities. Key players, including Novo Nordisk and Eli Lilly, are innovating with new formulations, distribution channels, and personalized therapies, positioning GLP-1 agonists as a cornerstone in global obesity management and weight loss treatment strategies.

Vaccine Market Product Estimates, Trend Analysis & Outlook by 2024

24 Jan 2019 - The global Vaccine Market was valued at over USD 32.5 billion in 2015 and is expected to reach over USD 77.5 billion by 2024, at a CAGR of 10.3%. A lot of vaccines technologies that could assist in improved safety, effectiveness and deliverance are in progress, such as needle liberated administration, escalating the magnitude and long lasting existence of defensive immune responses provoked by vaccines at the same time as plummeting the dose, and enhanced vaccine stabilization.

The worldwide industry for vaccines is expected to nurture, owing to technical advancements in admiration to the expansion of new vaccines towards cancers, rising infectious diseases and allergies. The industry will acknowledge constant progress in delivery methodologies, vaccine design, and manufacturing in huge scale process. The industry is expected to witness a drift towards the expansion of customized vaccines. In addition, to which the requirement for cost effective and safe drugs for the cure of HIV infection, many cancers which could be dealt by therapeutic vaccines, will outstandingly fuel the market growth over the forecast period. Inside the healthcare market, the vaccine market was originally considered a small profit venture but is presently professed with transformed interest among market circles owing to its huge demand in regard to rising infectious diseases. In addition, an enhanced and considerate understanding of the immune system has cemented new prospects for making new therapeutic and preventive vaccines. Rapid advancements in consideration of the immune system and wish of medical society to engineer both therapeutic and preventive vaccines for a wide-ranging field of diseases are expected to fuel the changes in the managed care industry and medicine industry which in return is expected to fuel the growth of the market. The expansion of worldwide Vaccine industry is partially fuelled by technical breakthroughs such as genome sequencing of contagious pathogens, sophisticated understanding of the immune system and its instrumentation of reaction, chased by a noteworthy influx of money from civic funding bodies, commercial organizations and private charity. Safety, the manifestation of adequately high efficiency and lack in a requirement of a reliable evaluation and development pathway are the main obstructing blocks for making new vaccines.

Request Sample Copy of this Market Research @https://www.millioninsights.com/industry-reports/vaccine-market/request-sample

Additionally, discovering novel and more efficient ways of healing rising public health threats, there is substantial focus on recovering access to immunization for people in developed and developing countries. There is an imbalance in demand to create effective vaccines in opposition to a number of lethal infectious diseases such as malaria, hepatitis C and AIDS. Even though, vaccines for Infectious diseases such as influenza and TB exist, but are only partly effectual and this sector demands significant upgrading to react for the actual public health needs. This imbalance is expected to pose the challenge for this market over the forecast period.

Browse Full Research Report @https://www.millioninsights.com/industry-reports/vaccine-market

On the basis of technology class, the market can be segregated into Conjugate Vaccines, Toxoid Vaccines, Sub-Unit Vaccines, Recombinant Vector Vaccines, Live/Attenuated Vaccines, DNA Vaccines, Synthetic Vaccines and Dentritic Vaccines. On the basis of the type, the market can be segregated into Therapeutic and Preventive. On the basis of end users, the market can be segmented into Adult and Paediatric. On the basis of disease indication, the market can be segregated into Infectious Diseases, Cardiovascular Diseases, Allergies, Cancer and Others such as Diabetes. On the basis of a geographical region, the market can be segregated into North America, Asia Pacific, Europe and Rest of the world. Asia Pacific is expected to grow rapidly over the forecast period owing to increasing demands of a vaccine in the countries like India and China coupled with rising awareness about the usage of vaccines. North America is expected to capture maximum revenue over the forecast period owing to great awareness of vaccine and increasing regulation by government to strengthen the vaccination process. North America is followed by Europe.

Some of the key players in the market are Sanofi, Glaxo SmithKline PLC, Merck & CO., INC., Novartis AG, Aduro biotech, ImmunoCellular Therapeutics Ltd, Antigen Express, INC, Agenus Inc, Galena Biopharma Inc., Dynavax Technologies Corp., and Inovio Pharmaceuticals. The companies are focused on initiating the DNA-supported vaccines to stop and cure cancer and infectious diseases. The market is less fragmented and there is the lack of standardization which is expected to pose the challenge for the players over the forecast period. As the number of contagious diseases is increasing, the key companies playing in this area try their best to incorporate latest innovations in their vaccines so that they can have more effective vaccines. This market is expected to be innovation driven over the forecast period.

See More Reports of this Category by Million Insights @ https://www.millioninsights.com/industry/pharmaceuticals

Cystic Fibrosis (CF) Therapeutics Market|Value Chain Analysis & Company overview 2025

18 Jan 2019 - The global Cystic Fibrosis (CF) Therapeutics Market is expected to be valued at USD 13.9 billion with CAGR of 16.7% over the forecast period. Cystic fibrosis (CF) is a severe disease that causes overall damage to lungs, digestive systems and other organs in the body. In this state, CF affects the cells that are responsible for sweat, mucus digestive and fluid juices. These juices are normally thin and slippery but patients suffering from cystic fibrosis experience thick blockage in lungs and other organs, as this affects the cells that regulate digestive and fluid juices causing them to become an obstacle rather than carriers. The cells instead of acting as a lubricant become sticky and thick, thus blocking up lungs, pancreas and other organs in the body. Medically this disease is termed as mucoviscidosis.

The major driving factors of this market rely significantly on extensive R&D. As the ongoing R&D activities have boosted the CF therapeutics market and witnesses a lucrative growth in the upcoming years. The other driving factors like awareness for cystic fibrosis therapy, technological advancements in R&D attribute to the success of market growth. However, high costs of treatment and R&D, entangled pathophysiology, rising rate in genetic mutation are some factors that may cause to hinder the market growth. On the basis of therapeutics, the global market is segmented into pulmozyme, TOBI, kalydeco, Cayston, Arikace, Aeroquin and others. Cystic Fibrosis Trans membrane Conductance Regulators (CFTR) modulators treat the root cause of disease rather than symptoms, resulting in improving the lives of patients. Kalydeco is the first CFTR modulator to enter the market and had a large impact on the value of market though it treated a small proportion of CF patients. Pricing will be premium for CFTR modulators due to the therapeutic benefits. Symptomatic therapies will continue to be a necessary part in conjunction with CFTR modules. Comparatively, the antibiotics segment is expected to gain second importance owing to the competitiveness and novel market entrants.

Request Sample Copy of this Market Research @ https://www.millioninsights.com/industry-reports/cystic-fibrosis-cf-therapeutics-market/request-sample

A multi-resistant superbug infection that can prove fatal for patients suffering from cystic fibrosis (CF) has spread globally and is becoming viral, according to the British researchers. Moreover, it has not only gone viral but is evolved and capable to jump from patient to patient, according Andres Floto, a Cambridge University professor. Adding further, he said that as the superbug has become resistant to various antibiotics; it is also difficult to treat it successfully. As a part of treatment infected patients may need more than a year of treatment with a combination of strong antibiotics and the ratio of cure is one in three. The market is segmented on the basis of geography which includes North America, Europe, Asia-Pacific, Middle-east and Africa. The European region dominates the global market scenario and is considered as the most fertile market which is also followed by North America. Asia-pacific regions are considered to be the least important market owing to less prevalence of the disorder. The key players include Novartis International AG, Chiesi Farmaceutici SpA, Vertex Pharmaceuticals, Genentech, Inc., and Gilead Sciences, Inc. Vertex Pharmaceuticals is the developer of kalydeco and expected to be a key player in the global market.

Browse Full Research Report @https://www.millioninsights.com/industry-reports/cystic-fibrosis-cf-therapeutics-market

See More Reports of this Category by Million Insights @ https://www.millioninsights.com/industry/pharmaceuticals

Superdisintegrants Market Dynamics And Demand In Emerging Regions by 2025

11 Jan 2019 - The global Superdisintegrants Market size was valued at around USD 258.6 million in 2016 and is expected to reach USD 487.0 million by 2025, with a CAGR of 7.2%. Superdisintegrants are the materials primarily used in the pharmaceutical preparation of tablets. Due to these materials, the medicinal substances used in the tablet get disintegrated and release their medicinal substances when they come in contact with moisture. Superdisintegrants are the materials or the combinations of materials added to the drug preparation that simplifies the breakup of tablet or capsule content into lesser atoms that liquefy faster than in the absence of disintegrants. The healing action of these preparations is acquired through a typical way alike disintegration followed by dissolution. Superdisintegrants are normally used at a small level in the hard dose method, classically 1-10 % by weight comparative to the total weight of the dose unit.

The worldwide market of the superdisintegrants is split by Product type (Natural, Synthetic, Others), Application type (Tablets, Capsules), Therapeutic area (Oncology, Neurology, Cardiology, Infectious Disease, hematology), and Geography (North America, Europe, Asia Pacific, and Rest of the World (RoW). The “synthetic” superdisintegrants market is further classified into crospovidone, modified scratch, ion exchange resins, calcium silicates, and modified cellulose. The synthetic segment dominates the market. North America leads the market; followed by Europe. The driving factors for this growth include development of new forms of oral dosage coupled with continuous efforts toward providing compliant and superior products. The other factors include increasing incidences of neurological diseases, cardiovascular diseases, and the other related diseases.

Request Sample Copy of this Market Research @https://www.millioninsights.com/industry-reports/superdisintegrants-market/request-sample

The Asia Pacific region is forecast to grow at the highest CAGR. This will be due to rising expenditure on the healthcare products and growing healthcare awareness, increasing healthcare infrastructure and outsourcing of excipient manufacturing to Asian countries, for example: China and India. This growth in the market is expected due to the rising population of elderly people, pediatric patients, the growing market for the generic drugs, and arrival of the new superdisintegrant materials. Yet there are certain factors which will restrict the growth of this market, for example the expenditure on the research and development is going down.

Browse Full Research Report @https://www.millioninsights.com/industry-reports/superdisintegrants-market

See More Reports of this Category by Million Insights @ https://www.millioninsights.com/industry/pharmaceuticals

Cyclospora Diagnostic Testing Market Snapshot, Landscape & Cost Analysis by 2025

8 Jan 2019 - Cyclospora is basically an intestinal ailment that is affected via the microscopic parasite termed as “Cyclospora cayetanensis”. Cyclospora Diagnostic Testing Market size on the basis of end-users spans commercial or private laboratories, hospitals, public health labs and physician offices. It is a single-celled coccidian parasitic pathogen that triggers intestinal infection that leads to diarrhea. When we look at it in the medical terms, this diarrheal infection is labeled as cyclospora infection (cyclosporiasis). It is known that this particular infection is usually spread and communicated via feces and ingestion of food and water infected with sporulated oocysts.

Through studies, it has been found that people can be infected with Cyclospora by taking in food or water that is polluted and tainted with the parasite. Those people are at great risk for infection that stay in those countries or travel to regions where cyclosporiasis is quite prevalent. It is said that cyclospora diagnostic testing is not a regular laboratory test. It is only taken up following exact and particular requests from specialized physicians and doctors. The most fundamental laboratory tests that are carried out for Cyclospora entail acid-fast staining and safranin staining. Even though there are a wide range of tests available, it is quite fascinating to know that there are no blood tests available for the treatment of Cyclospora infection. The prominent factors that are playing a major role in raising the demand for cyclospora diagnostic testing include augmented modernization, improvement in technology, and rising concerns for health related issues.  Cyclospora Diagnostic Testing Market size on the basis of techniques used for diagnosis spans chromatography, diagnostic imaging, gel microdroplets, immunoassays, liposomal testing, differential light scattering, flow cytometry, monoclonal antibodies, and molecular diagnostics. Cyclospora Diagnostic Testing Market size on the basis of geography spans North America, Asia Pacific, Europe, and Rest of the World.

Request Sample Copy of this Market Research @ https://www.millioninsights.com/industry-reports/cyclospora-diagnostic-testing-market/request-sample

As far as the geography is concerned, Asia Pacific is lately dominating the Cyclospora Diagnostic Testing market and it is also recognized as the largest market for these tests owing to more susceptive surrounding for infection. The data shows that this particular disease is quite prevalent in tropical and subtropical countries of Latin America and Asia.

Browse Full Research Report @https://www.millioninsights.com/industry-reports/cyclospora-diagnostic-testing-market

In addition, latest irregular occurrence of the infection has also been observed in temperate countries including the U.S., Canada, and Mexico. The data that has been revealed from the studies of the Centers for Disease Control and Prevention states that above 600 cases of Cyclospora infection were witnessed in 2013, because of the infection communicated via the means of packaged salad mix. The key players operating in the cyclospora diagnostic testing market include Roche Diagnostics, Siemens Healthcare, Diamedix Corporation, Hologic, Inc., DiaSorin S.p.A., Thermo Fisher Scientific, Inc., QIAGEN N.V., Wako Chemicals, Inc, Affymetrix, Inc., Nanogen, Inc., Ortho Clinical Diagnostics, Beckman Coulter, Inc., bioMerieux, Inc., and CEPHEID.

See More Reports of this Category by Million Insights @ https://www.millioninsights.com/industry/pharmaceuticals

DNA Vaccines Market Restraint Analysis & Company Forecast by 2025

4 Jan 2019 - DNA Vaccines Market represent a holistic view as a protection against infectious disease and may enhance human and animal welfare, minimize antibiotic usage and also curtail the proliferation of pathogens. Injectable and edible DNA vaccines exhibit a determined approach for rapid immunization against several diseases that are problematic to eliminate traditional vaccines and antibiotics. Other potential uses of DNA vaccines are inclusive of autoimmune disease, allergies, and treatment of cancer. On the basis of geographic segmentation, the global DNA vaccines market spans North America, Latin America, Asia-Pacific, Middle-East, and Africa.

Other potent uses of DNA vaccines include low cost, ease of production and enhanced quality on heat stability, identical production processes for different vaccines. A DNA vaccine comprises a bacterial plasmid that induces the immune system. When a patient is administered with the DNA vaccine, the mechanism in their cells make a viral or bacterial protein in which their immune system considers as alien to the body. DNA vaccines are different to conventional vaccines are made up of bacteria or viruses or a part of bacteria or virus such as protein. Advantages in using the DNA vaccines can be summed as such vaccines need short time span, easy to transport and service, are very cheap to make, and there is no risk to those who are involved in making the vaccine. Disadvantages include initial attempts to create DNA vaccines are less significant on consumption by human body and most of the DNA vaccines are not open for human use yet. Therefore, considering the pros and cons coupled with market dynamics, the global market for DNA vaccines witnesses a higher CAGR growth during the forecast period. The key driving factors responsible for the growth of DNA vaccines market include growing vulnerability of population to infectious disease and rising number of antibiotics resistant pathogens have generated the need for effective and low cost vaccination which would provide lasting immunity.

Request Sample Copy of this Market Research @https://www.millioninsights.com/industry-reports/dna-vaccines-market/request-sample

On the basis of disease type, the global DNA vaccines market is segmented into human DNA vaccines and animal DNA vaccines. Human DNA vaccines market is further segmented into HIV infection, cancer and infectious diseases.

Browse Full Research Report @https://www.millioninsights.com/industry-reports/dna-vaccines-market

On the basis of technology, the global DNA vaccines market is segmented into pDNA vaccines technology and pDNA delivery technology. pDNA vaccines technology is further sub-segmented into therapeutic technology and preventive technology. pDNA delivery technology is further sub-segmented into uncomplexed pDNA, liposomes, gold particles, electroporation, bacteriophages, bacterial ghosts, nanoparticles and viruses.On the basis of application, the global DNA vaccines market is segmented into human diseases, and veterinary diseases. Human diseases are further sub-segmented into oncology, allergies and infectious diseases. Oncology is further sub-segmented into pancreatic cancer, breast cancer, ovarian cancer, small cell lung cancer and melanoma. Infectious disease is further segmented into CMV, HBV, HCV, HIV and Influenza. Veterinary disease is further sub-segmented into canine melanoma, leishmaniosis, and Equine West NileVirus. The key players in the global DNA vaccines market spans Novartis Animal Health, Inovio Biomedical Corp, Merck & Co, Dendreon Corporation, Pfizer pharmaceuticals, GlaxoSmithKline, Advance Bioscience Laboratories Inc, Indian Immunologicals Ltd, Xenetic Biosciences Inc, QED Biosciences Inc, Astellas Pharma, Vical, Sanofi and Tekmira Pharmaceuticals.

See More Reports of this Category by Million Insights @ https://www.millioninsights.com/industry/pharmaceuticals

Borage Oil Market Restraint Analysis & Company Forecast by 2024

2 Jan 2019 - Global Borage Oil Market was estimated at 1,500 tons in 2015. Nutraceuticals and bio-based cosmetics are anticipated to be the key factors influencing market growth over the forecast period. The global borage oil market is anticipated to reach USD 54.9 million by 2024. High gamma linolenic acid (GLA) content has resulted in high demand for Borage (starflower) oil despite several other plant oils including evening primrose oil and black currant seed oil containing GLA and providing similar health benefits, borage oil has gained prominence owing to higher GLA content compared to its counterparts. For instance, black current seed oil contains nearly 14% to 17% and evening primrose contains approximately 10% to 15%. On the other hand, GLA content in borage oil is approximately 20% to 25%. GLA is rich in omega-6 fatty acid which is essential for the human body, but the human body is incapable of producing the same by itself which necessitates the external supply of GLA. Borage oil benefits consumers by effectively treating and preventing health disorders pertaining to fatty acid metabolism.

Borage crop is cultivated in several countries for its seed oil. Majorly produced in Canada, New Zealand and the UK, in earlier times it was considered to belong only to the Mediterranean region. The borage oil production varies widely with some years of oversupply and some years of under-supply. Canada, which is one of the major borage seed producers has been highly unstable in the recent times. Favorable weather conditions in Canada have benefitted borage growers to a great extent as it helps them grow good quality seeds at lower costs. Nevertheless, there is a high risk of crop failure due to erratic early frost in the region. Borage seed prices lie in the range of USD 2.5 to 4 per kg and the production varies between 500 to 2000 tons per annum. Such high variations in the raw material supply and their prices are anticipated to be the major restraining the factor affecting market growth.

Request Sample Copy of this Market Research @https://www.millioninsights.com/industry-reports/borage-oil-market/request-sample

Application Insights

In 2015, medical application segment constituted for more than 35.0% of the overall borage oil demand. Borage oil aids in the treatment of serious diseases including obesity, eczema, rheumatoid arthritis, heart disease, premenstrual syndrome, cough, stroke, depression, asthma and diabetes. Borage oil is used as a combination with other base oils in the nutraceutical segment. Additionally, it is used as anti-inflammatory drugs. With the market growing at a CAGR of above 5%, along with being the largest segment, the medical sector is anticipated to be the fastest-growing application over the forecast period. Further, borage oil capsules that have several health benefits are also available in the market. Borage oil is widely used in the cosmetics segment including cleansers, moisturizers, skin care and anti-aging products, hair treatment and body care owing to their antioxidant and anti-inflammatory properties. It is used as food additives in functional foods, meal supplement and breakfast cereals.

Browse Full Research Report @https://www.millioninsights.com/industry-reports/borage-oil-market

Regional Insights

Borage oil has widespread usage across cosmetics and pharmaceuticals industry witness major demand in the Asia Pacific region. Asia Pacific borage oil market dominated the market and contributed to over 30% of overall demand in 2015. This huge demand can be ascribed primarily to growing production levels of pharmaceutical drugs, cosmetics and nutraceuticals. Pharmaceutical and cosmetic manufacturers have been focusing on developing countries such as India, China and Indonesia as their major manufacturing units. This has propelled demand for raw material supplies in the region. Borage oil market in North America is anticipated to be driven on account of growing demand for natural and organic cosmetics. North America starflower oil market is projected to grow at an estimated CAGR exceeding 5% in the next eight years. Constant efforts by research institutions in order to identify the medical potential of borage oil are anticipated to improve the overall consumption level from 2016 to 2024. Additionally, the region has been concentrating on enhancing starflower oil consumption in food application such as functional food additives and dietary supplements. Europe is a prime location for borage oil production owing to its favorable soil and weather conditions. High GLA and oil content in UK grown starflower make it the best quality seed available in the market. The presence of large skincare and haircare producers including Unilever and L’Oréal are expected to serve the European market and result in high starflower oil demand over the forecast period. These companies have been emphasizing on bio-based cosmetic development that is expected to augment market demand.

Competitive Insights

Global borage oil industry is fragmented in nature on account of the presence of several small-scale manufacturers. Borage oil manufacturers attempt to procure good quality seeds produced in Canada and UK in order to achieve a competitive edge as high-quality oil is ideal for premium applications. Major borage oil manufacturers include Connoils LLC., Aromex Industries, Desert Whale Jojoba Company, Oilseed Extraction, K. K. Enterprise, Nordic Naturals, AOS Products Pvt. Ltd., IcelandirectInc and Soyatech International Pvt. Ltd.

See More Reports of this Category by Million Insights @ https://www.millioninsights.com/industry/pharmaceuticals

Pharmaceutical Packaging Market: In-depth, Product Segments & Application to 2025

27 Dec 2018 - The global Pharmaceutical Packaging Market was appreciated at US$ 77.65 Billion in the year 2016. The market is estimated to develop at a substantial CAGR for the duration of the prediction. The market is expected to observe considerable development due to the increasing demand for pharmaceuticals from developing markets. These products have increased much importance from the time when the previous few years such as they help in defending medications and pills in contradiction of disapproving exterior features for example biotic adulteration, physical injury, deprivation, and imitating.

Developing market places for example Turkey, Brazil, Russia, India, and China are giving an exceptional development opening for the pharmaceutical manufacturing. The growth in contract out of pharmaceutical production to developing markets likely to expose new-fangled ways for the development of the market. The constancy of these markets together with promising administration strategies likely to take an optimistic influence on the pharmaceutical packaging market demand.
The Pharmaceutical Packaging market on the source of Type of End Use could span Official Drug store, Contract Packaging, Retail Drug store, Medicine Manufacturing, and others. The subdivision of Medicine manufacturing estimated to lead the general end-use section due to the existence of internal packing amenities in the production plants of manufacturing members. The site where the medicines manufacturing takes a deep impression on the end-use ingestion of packaging products due to which medicinal production estimated to continue the most important end-use above the prediction period.
The Pharmaceutical Packaging on the source of Type of Product could span Tertiary Packaging, Secondary Packaging [Pharmaceutical Packaging Accessories, Prescription Containers], Primary Packaging [Medication Tubes, Prefill able Inhalers, Parenteral Containers, Plastic Bottles, Pouches, Blister Packs, Caps & Closures].

Request Sample Copy of this Market Research @ https://www.millioninsights.com/industry-reports/pharmaceutical-packaging-market/request-sample

The demand for primary packaging products is normally greater in the market such as they straight are in contact with the drugs. Secondary and tertiary products are important to the market but then again their intake estimated to go on downcast owing to a smaller amount capacity involved in the delivery of the ultimate manufactured goods.

Browse Full Research Report @https://www.millioninsights.com/industry-reports/pharmaceutical-packaging-market

The subdivision of Secondary pharmaceutical packaging estimated to develop by a CAGR of 7.5% for the duration of prediction. The subdivision includes preparation ampoules and equipment. The demand projected to develop speedily due to growing intake of primary pharmaceutical packaging merchandises. The Pharmaceutical Packaging market on the source of Type of Material could span Aluminum Foil, Paper & Paperboard, Glass, Plastics & Polymers [PVC, Polyester, LDPE, and HDPE], and others. The Pharmaceutical Packaging industry on the source of Area with respect to Trades in terms of intake, Profits, Market stake and Development percentage in these areas, for the duration of the prediction could span North America [U.S.A], Europe [France, Germany], Asia Pacific [India, Japan, China],Central & South America [Brazil], Middle East & Africa.
By the source of geography, North America held the biggest provincial stake of more than 40%, in the market in the year 2016. The demand in this area, motivated by U.S.A. Here the sum of new-fangled product presentations, by means of dedicated wrapping requirements is increasing speedily. In this area, the existence of most important medicinal producers for example Novartis and Pfizer is motivating the progress of the market.

The European market is likely to develop at a reasonable speed because of go-slow in this area. The Western European market estimated to observe speedy development due to governing force relating to wrapping of drugs and increasing demand for anti-imitation wrapping. The existence of different medicine manufacturing companies in Japan, India and China is motivating the demand for merchandises in the area of Asia Pacific. The area is advancing from the existence of a huge number of corporations, producing wide-ranging medications. The increasing generics production together with a growth in contract wrapping expected to increase the development of the market above the prediction period.

The statement revises Trades in terms of intake of Pharmaceutical Packaging in the market; particularly in North America, Europe, Asia Pacific, Central & South America and Middle East & Africa. It concentrates on the topmost companies operating in these regions. Some of the important companies operating in the field on the international basis are COMAR LLC, Berry Plastics Group, Capsugel, Becton Dickinson & Company, West Rock Company, Owens-Illinois, and Aptar Group Inc., West Pharmaceutical Services, Inc., Amcor Ltd., Gerresheimer AG., Schott Pharmaceuticals Services Inc., MeadWestvaco Corporation and RPC Group. Additional notable companies operating in the field on international basis are Plastube Inc., Unilife Corporation, Baxter International Inc., 3M, Anchor Packaging, Exporta Global, Centor and Lilly (Eli) Company, Sealed Air Corporation, Ball Corporation, West rock and CA talent Pharma Solutions Inc.

See More Reports of this Category by Million Insights @ https://www.millioninsights.com/industry/pharmaceuticals

Decoquinate-Based Products Market Snapshot trends & Company Overview by 2025

21 Dec 2018 - Decoquinate (ethyl 6-decoxy-7-ethoxy-4-oxo-1H-quinoline-3-carboxylate) is an antiprotozoal agent. It acts against coccidia parasites and is thus known as a coccidiostat. Decoquinate-based products are majorly used in veterinary medicine. The global decoquinate-based products market is segmented on the basis of type of formulation, and geography.  Decoquinate acts on the sporozoite stage of a coccidian parasite’s lifecycle. The sporozoite can penetrate the host’s intestinal call and prevents their further development, which necessitates the use of antiprotozoal substances. Decoquinate has low toxicity and is administered orally to a wide range of mammalian and avian species.

Various studies conducted on decoquinate-based products suggest that the drug is readily tolerated by several target species including cattle and lambs. On the other hand, studies conducted on rats and dogs showed minor changes in food consumption, feed conversion, subdued behavior, and changes in body weight and organ weight. In conclusion, though there may be a minor risk posed by decoquinate-based products, the protection it provides against coccidian parasites comfortably outweighs it.

On the basis of type of formulation, the global decoquinate-based products market is segmented into powder, tablet, and nanoparticles and so on. “Powdered decoquinate” dominates the global decoquinate-based products industry owing to its ease of usage. Powdered decoquinate-based products can easily be added to animal feed, which also helps the drug get absorbed into the animal’s body at a rapid rate. However, nanoscale decoquinate-based products comprise the fastest growing segment of the global decoquinate-based products market due to the added advantages nanoparticles provide over powders. The smaller size of nanoparticles means they can be absorbed into the animal’s body even quicker than powders.

Request Sample Copy of this Market Research @ https://www.millioninsights.com/industry-reports/predictive-breast-cancer-gene-testing-market/request-sample

The increased overall surface area of nanoscale decoquinate-based products also means they are more reactive and more likely to encounter a coccidian parasite. On the basis of geography, the global decoquinate-based products market is segmented into Asia Pacific, North America, Europe, Latin America and Middle East & Africa.

Browse Full Research Report @https://www.millioninsights.com/industry-reports/decoquinate-based-products-market

North America and Europe currently dominate the global decoquinate-based products market due to the strong economic conditions and the large population of cattle in these regions. The Europe market for decoquinate-based products is driven by the rising demand from Switzerland which is known for its large dairy industry.  Additionally, several governments in North America and Europe have also set up regulatory agencies which have also been instrumental in the growth of the global decoquinate-based products market. These government bodies provide funds for developing novel veterinary biologics and animal health products such as antibodies, vaccines, diagnostic kits which are used for the prevention, diagnosis and treatment of infectious diseases in animals.

The Asia Pacific market for decoquinate-based products is also growing rapidly due to the increasing awareness about the benefits of decoquinate among cattle and poultry breeders. The key players of global decoquinate-based products market are Alpharma, Pfizer Inc., 3 nitro, ChlorMax, Albac, Lincomusin, Laboratories Biove’s acti decocci and lacto decocci, Sogeval Laboratories Rumicox, Pharmacia & Upjihn Company’s Lincomix and Qualian’s Ucamix V decoquinate.

See More Reports of this Category by Million Insights @ https://www.millioninsights.com/industry/pharmaceuticals

Human Growth Hormone Drugs Market Snapshot. Landscape & Key Buying Criteria by 2020

26 Nov 2018 - The global Human Growth Hormone Drugs Market is expected to witness growth over the forecast period on account of growing population worldwide. It is observed that HGH related problems affect teenagers and children largely; however, it is seen to hold adults also although to a lesser extent. The key factors which impair the pituitary operations thus damaging the GH role include kidney malfunction, tumours and cancer particularly related to the brain. There are some other unknown causes as well which are termed as idiopathic which are expected to drive the sector growth over the next eight years. Previously, to deal with these difficulties, HGH used to be extracted, however, on account of technological advancement and research and development, the extraction of GH has reduced which in turn fuelled the product demand.

The pituitary gland is a key gland in the human endocrine system which is accountable for regulating crucial hormonal secretion, which, in turn, regulates other major aspects of the body such as temperature control, growth, production of hormones, urination, and thyroid functioning. Pituitary gland is a key constituent of the human body as it advances the reaction towards the surrounding environment and the size of the gland is comparable to a pea which is located at the base of the brain. In cases of damage and improper functioning in the growth, formation and operations of the pituitary gland the human body will suffer from various dysfunctional body processes related to hormones. The growth hormone is medically stated to be somatotropin. When pituitary gland malfunctions, it either secretes less HGH than required or more than required on account of which in cases of less secretion there is restriction of growth in the body, organs and limbs which will lead to dwarfism, while in case of more than required secretion there is excess growth in limbs and peripheral abnormalities arise which lead to gigantism, disfiguration in the body parts including, face and feet.

Request Sample Copy of this Market Research @ https://www.millioninsights.com/industry-reports/human-growth-hormone-drugs-market/request-sample

The major trends which include continuous increase of recombinant growth hormones industry and increasing use of bio-similar drugs and an agreement for long acting (HGH-CTP) human growth hormone. On the industry development front, the current inclination is towards developing needle free injections technology and better treatments for Alzheimer's disease. In addition, the major factors driving the HGH industry include rising cancer, CKD and ESRD cases and increase in healthcare expenditure on a global level in past few years. Factors which are expected to pose challenge to the industry include the issues in diagnosis of HGH deficiency, hazards associated with the usage of recombinant growth hormone therapies and use of HGH without label, to a certain level, are expected to hinder the growth and development of the product industry.

Browse Full Research Report @ https://www.millioninsights.com/industry-reports/human-growth-hormone-drugs-market

The segmentation of the market includes the market for treatment of growth hormone deficiency in adults and children and the vanity sector which uses the growth hormone for enhancing the body performance, however, FDA does not recommend these uses hence they are less worthwhile. The malformations in the pituitary and abnormalities in the growth hormone secretion levels majorly impacts children and teenagers worldwide. Therefore, there are a large number of consumers who need the drugs which treat growth hormone related health issues for children and adults. The pharmaceutical industry is being allocated with a lot of funds for research and development for the betterment of drugs related to growth hormone which offer greater sustained release and longer action periods. The growth of this sector is also fuelled on account of the modernization in the methods of delivery of the hormones. The prescription products including Saizen, Humatrope, Genotropin and Norditropin are highly sought and viable for therefore having a higher price.
Europe is observed to be the dominating the industry from the past few years on account of excessive research and development and technological advancements in the sector, followed by North America. The Asia Pacific and China are expected to be the lucrative market for the product owing to the large population.  The major market players operating in the market include Pfizer, Merck Serono, Anhui Anke Biotechnology, BioPartners, Ferring Pharmaceuticals, GeneScience Pharmaceuticals, Ipsen, LG life sciences, Sandoz international, Teva Pharmaceuticals, NovoNordisk, Eli Lilly, and Roche.

See More Reports of this Category by Million Insights @ https://www.millioninsights.com/industry/pharmaceuticals

Nanoparticles - Metal & Metal Oxides Market Raw material & overview 2025

12 Nov 2018 - Global Nanoparticles - Metal & Metal Oxides Market size was worth USD 25.86 billion in 2016 which is anticipated to grow at a CAGR of more than 13.7% over the forecast period.

The existence of a significant amount of metal and metal oxide nanoparticle based drugs that are authorized by the U.S. FDA and prescribed by physicians for the treatment of acute and chronic ailments is attributive for the estimated market.
Furthermore, presence of molecules in the development phase based on the principle of metal oxide nanoparticles is anticipated to boost growth in the coming years. Applications served by these particles include radiotherapy enhancement, drug & gene therapy, thermal ablation, and sensitive diagnostic assay.
This versatile nature with respect to the applicability in health care makes these particles a substantial source of growth in nanomedicine market. Technological innovations pertaining to reduction of adverse effects linked to the application of these particles is expected to influence growth in the forecasted period.
Scientists and biologists are currently involved in directing R&D to improve understanding of metal based nanoparticles in order to lessen the toxicity problems associated with their usage. Subsequent developments are anticipated to fast-track the development over the forecast period. The pharmaceutical field is a continually progressing marketplace with vigorous regulatory standards, growing demand for outcome oriented therapy and rising manufacturing and R&D costs for delivering better products than the existing ones. These concerns are persistently generating pressure on manufacturers and government policy makers to meet patient expectations for providing better drugs at a low price.

Request Sample Copy of this Market Research @ https://www.millioninsights.com/industry-reports/nanoparticles-metal-oxides-in-healthcare-market/request-sample

Research endeavors carried out for developing novel products is anticipated to boost revenue generation in the coming years. Additionally, the presence of government supported plans such as the National Nanotechnology Initiative (NNI), which offers provision to co-ordinate projects of R&D for nanomedicine technology growth are factors anticipated to strengthen the revenue potential of nanotechnology industry in healthcare.

Browse Full Research Report @ https://www.millioninsights.com/industry-reports/nanoparticles-metal-oxides-in-healthcare-market

Type Insights

Gold particles have the biggest share with respect to revenue owing to their vast use in therapeutic advancement. Key factors include small dimensions, less toxicity, and better compatibility that aid in increasing its adoption rate.
Besides, gold nanocages coupled with the coating of the temperature-sensitive polymer are pertinent in a targeted delivery system that on contact with near-infrared radiations, discharge effectors. These are beneficial in checking for interaction with the drug and avails efficient control, thus driving adoption in the various delivery application of the drugs reaching from DNA to the cellular level, disease monitoring, imaging and diagnosis.

Application Insights

In-vivo imaging is projected to contribute for the largest share in terms of revenue due to growing adoption of nanoshells, for example, Au3Cu1 that claims to provide better contrast for blood vessels which can be used in vivo MR angiography.

Regional Insights

North America dominated with the largest revenue share owing to the existence of clear regulatory guidelines for therapeutic development. Furthermore, with the increasing collaboration between key stake holders including government agencies, lawmakers, health insurers, and pharmacy benefit managers, better outcome based products can be produced with a check on relevance in the market.
This region is also witnessing inter-country collaboration on the production and usage of nanotechnology based products. For example, Canada and the U.S. collaborated on the development of nanomaterials under the Regulatory Co-operation Council (RCC). As a result, the nanotechnology work plan of the region was made and the conference took place in Washington, DC in January 2014.
Asia Pacific is anticipated to exhibit the fastest growth over the forecast period. Factors responsible for the projected CAGR include growing investment in the development of nanoparticles coupled with a surge in the amount of clinical studies that can aid in determination of toxicity of these products.
Corporations across Asia, especially in China and India, are increasing their spending in research projects on the utilization of nanomolecules which is anticipated to support the progression of this market in Asia pacific region.

Competitive Insights

Key companies working for the development of metal and metal oxide nanoparticles include Nanobiotix, AstraZeneca, Pfizer Inc., nanoComposix, Merck KGaA, Nanospectra Biosciences, Immunolight LLC, Women’s Hospital and Brigham.
Pharma-biotech entities are engaged in R&D and are carrying out enormous capital investments. Product advancement in human therapeutics and rising demand for better outcomes by the treatment provided are anticipated to boost progress in the coming years.

See More Reports of this Category by Million Insights @ https://www.millioninsights.com/industry/pharmaceuticals

Nanomedicine Market Restraint Analysis & Industry Outlook by 2025

5 Nov 2018 - The global Nanomedicine Market size was worth USD 138.9 billion in 2016 which is anticipated to grow at a CAGR of more than 9.8% during the forecast period. Factors such as technological advancements along with significant applications in the prophylaxis of acute and chronic diseases, prevention intervention, and early disease diagnosis are accountable for progress of this industry. Miniaturization of bigger chemicals and structures at nanometric scale enables the modernization in drug administration thus leading to growth in nanotechnology market for healthcare industry.

Advancements in nanorobotics due to the escalation in funding from the government bodies are accountable to persuade potential to the nanomedicine market. Moreover, nanorobotics engineering projects which are targeting only the cancer cells without affecting the contiguous tissues is expected to promote progress through to 2025.
Factors such as the capability of nanotechnology to assist in both therapeutic and diagnostics sector simultaneously are accountable for a large number of researches which are undergoing in this sector. Moreover, application of DNA origami in the healthcare is accountable for the projected CAGR.
Furthermore, pipeline products based on the nano-molecules and related technologies are expected to promote the progress over the forecast period. Other factors such as, presence of number of products in phase II trial of clinical development and personalized treatment option is also available which is accountable for the development of nanotechnology for health care in the coming years.

Product Insights

In 2016, the foremost share was accounted by therapeutics owing to the existence of various products such as drug delivery systems, devices, and drugs falling in this classification.

Request Sample Copy of this Market Research @ https://www.millioninsights.com/industry-reports/nanomedicine-market/request-sample

Number of therapeutic drugs that can be delivered through nano methods is increasing with the inclination of pharmaceutical companies towards these research activities.
Nanotechnology is a promising technology which delivers drugs at the site of action with an enhanced cellular penetration and reduced toxicity. The aforementioned fact, is supportive for the estimated share of therapeutics segment. Moreover, development of innovative delivery products by using various kinds of nanoparticles is anticipated to boost the market growth.

Browse Full Research Report @ https://www.millioninsights.com/industry-reports/nanomedicine-market

Application Insights

Based on application, the segment incorporates cardiology, infectious diseases, oncology, and other applications. In 2016, oncology segment dominated with approximately 47% revenue share.
Rise in the R&D and funding activities in this segment is attributive for the larger share of this segment. Moreover, continuous increase in the incidence of oncology diseases is attributive for the development of nanotechnology based products for cancer eradication.
Cardiology is expected to witness fastest growth as a result of higher demand in the projected period due to several opportunities such as implants for tissue regeneration, nanostructured stents, and therapeutic nano-vectors.

Nanomolecule Type Insights

The capability of nanoparticles to get linked with the chemical moieties in different forms such as scaffolds aids in performing different functions. Moreover, application of nanoparticles for active targeting by linking it to cell receptor’s ligands is expected to drive progress potentially nanotechnology.
Metal and metal oxide is expected to witness substantial demand due to its widespread utilization in diagnostics. These nanoparticles enable diagnosis through the unique properties of different metals and metal oxides.
Dendrimers and the inorganic nanoparticles are also anticipated to grow at a potential rate in the coming years as consequence of research carried out in these segments. Furthermore, rising inclination of physicians towards nanodevices for monitoring and prognosis is anticipated to boost demand in the coming years.

Regional Insights

The nanomedicine market was dominated by North America with over 42% of revenue share due to escalating partnerships between nanomedicine startups and enterprises. Moreover, assistance from government organizations along with higher R&D expenditure is accountable for the largest share of the province in this sector.
Asia Pacific is anticipated to witness fruitful growth owing to factors such as rising demand for prophylaxis of life-threatening diseases and increase in a number of research grants. The escalation in a number of venture capital financiers and rising international research associations are expected to promote the nanomedicine growth in this region.

Competitive Insights

Several vital players are functioning in this market such as Teva Pharmaceutical Industries Ltd, Nanosphere, Inc., Celegene Corporation, Ablynx NV, GE Healthcare, Arrowhead Research, and Combimatrix Corp. These players are engaged in attaining the U.S. FDA approvals in order to enhance their revenue share.
Rising penetration of the companies in diverse segments with respect to nanotechnology in order to replace the conventional options of treatment and diagnosis is anticipated to lead in growth in the coming years. Market entities are engaged in collaborations with research institution and academic organizations in order to carry out active research.

See More Reports of this Category by Million Insights @ https://www.millioninsights.com/industry/pharmaceuticals

Active Pharmaceutical Ingredients (API) Market Research Methodology, Scope & Assumptions by 2014-2025

5 Oct 2018 - The Global Active Pharmaceutical Ingredient (Api) Market size was worth at USD 134.2 billion in the year 2015 which is anticipated to reach a value of USD 239.8 billion by 2025, with CAGR of 6.0%. Rising prevalence of chronic diseases such as neurological diseases, cardiovascular diseases, can lead to the growth.

The key drivers can be the rising demand of efficient and rapid acting drugs and introduction of innovative drug production facility. Major key players are choosing for outsourcing the product from the developing regions such as India, Brazil and China, which also anticipated to drive the market.
In addition, pharmaceutical companies face tremendous loss in terms of revenue owing to the patent expiration of blockbuster drugs. Expiration of patent results in increasing focus for development of generic versions of the molecules. The R&D investment of the company are no longer valuable after patent expiration. Thus, the API outsourcing trend in rising.

Synthesis Type Insights

Based on synthesis type, the market is categorized into synthetic and biotech. Various methods are adopted by the manufacturing companies depending up on the complexity of the molecule required. Synthetic drugs are manufactured on the basis of organic chemistry in contrast to biotechnology based drugs, which are produced by utilizing molecular techniques. Further classification of biotech segment is recombinant proteins, monoclonal antibodies and vaccines.
In 2015, synthetic segment held the largest share.

Request Sample Copy of this Market Research @                          https://www.millioninsights.com/industry-reports/active-pharmaceutical-ingredients-api-
market/request-sample

The key factors for the biotech APIs segment growth are large R&D investment for new biosimilars, increasing demand for protein-based medicines, and rising focus of key manufacturers toward biological drugs.

Manufacturer Type Insights

Based on the type of manufacturer, it is categorized into outsourced or merchant or in-house or captive APIs. According to market estimates, in 2015, in-house APIs was the largest segment and outsourced APIs are anticipated to be the fastest growing market.
All pharmaceutical companies does not have separate unit for the formulation of API. This has led to rise in the outsourcing of the molecules from the production sites. The need of investment in expensive production processes is eliminated by the outsourcing.

Type Insights

Based on the type, APIs are classified into innovative and generics. Branded products come under innovative type, whereas the generic drugs are the ones, which are available OTC (over the counter). Owing of high rate of prescription, high drug development initiatives, and high price, the innovative APIs segment dominated in 2015.

Browse Full Research Report @                                                      https://www.millioninsights.com/industry-reports/active-pharmaceutical-ingredients-api-market

Generic segment is anticipated to be fastest-growing type, due to expirations of patents of various blockbuster drugs. Patent expirations of branded drugs have very serious negative impacts on the drug producers, as the companies face the tremendous loss after expiration. Hence the drug manufacturers prefer more generic drugs than the branded ones.

Application Insights

Cancer, neurological disorders & CNS, endocrinal disorders and cardiovascular diseases are some of the major applications of the API. In 2015, CVD (cardiovascular diseases) dominated the market owing to its high rate of prevalence and high product availability. CVD has been reported as the major cause of death in the U.S since many years.
In addition, oncology is expected to be the fastest-growing segment and is estimated to witness the CAGR of 7% owing to high number of products waiting approval. Moreover, increasing prevalence of cancer worldwide is anticipated to further boost market.
 
Regional Insights

In 2015, API market was dominated by the North America and is anticipated to retain its position in upcoming years owing to encouraging government initiatives for generic drug usage, rising R&D expenditure, and technological advancements in the drug manufacturing practices.
Asia Pacific is anticipated to be the region with fastest growth owing to the increasing availability of cheap and affordable labour. Hence, key major companies are setting up their API production plants in developing countries of Asia Pacific such as China and India.

Competitive Insights

One of the key manufacturers of the API (Active pharmaceutical ingredients) is Teva Pharmaceuticals Ltd. Some of the additional key players in this industry includes Boehringer Ingelheim GmbH, AbbVie, Inc., Merck & Co., Inc. and Cipla, Inc., New molecule launches, collaborations, acquisitions, and regional expansions are some strategic initiatives taken by these Key players to retain their position.

See More Reports of this Category by Million Insights @ https://www.millioninsights.com/industry/pharmaceuticals

Excipients Market - SWOT Analysis, By Factor (Political & Economic) by 2020

4 Oct 2018 - Global Excipients Market size was worth USD 3.47 billion in 2013 which is anticipated to grow at a CAGR of more than 6.0% over the forecast period. Rise in demand for the generic drugs and the formulation additives required for the purpose of formulating these drugs is anticipated to drive excipient market in the coming years.

Development of a drug in diverse formulations requires a range of binders, disintegrants, and other chemicals that maintain or retain the characteristics of a drug moiety. Rise in disease prevalence as a consequence of increasing geriatric population is expected to increase the demand for pharmaceutical products, thus impacting the excipients demand over the forecast period.

Ongoing investigations for the development of suitable chemicals with ideal characteristics for a given formulation is are anticipated to boost growth in this sector. Adoption of novel delivery models that fuel the demand for enhanced chemical structures that are more stable and active in nature is expected to support in the projected growth. Treatment of the complex diseases pronounces the demand for complicated delivery methods that in turn drive the R&D in this sector thus leading to substantial progress in the coming years.

Product Insights

Polymer excipients accounted for the largest revenue share in context with revenue generation owing to its higher usage in several drug formulations. Advantages associated with the usage of this category of excipients include its changing property with changing concentration in different kind of dosage forms.

In addition to this, the multi-functionality of these products is anticipated to induce its adoption in several dosage forms thereby leading to its substantial growth. Use of polymers in the sustained and controlled release medication is attributive to support growth.

Request Sample Copy of this Market Research @                      https://www.millioninsights.com/industry-reports/excipients-market/request-sample

Regional Insight

European region dominated with largest share in 2016. High demand for pharma products due to high base of geriatric population and established sophisticated infrastructure to answer the healthcare needs are the factors owing for its estimated share. North America accounts for the second largest share in market, owing to a large base of pharmaceutical companies in this region.

Asia-Pacific region is expected to gain significant market share, growing at lucrative CAGR owing to the high prevalence of the chronic disease and rising investment by MNCs who outsource their products due to low manufacturing cost and supportive government policy.

In the coming years, development in the drug delivery system and high investment in R&D for improving dosage form technology is anticipated to fuel strong growth over the forecasted period.

Browse Full Research Report @                                                        https://www.millioninsights.com/industry-reports/excipients-market

Competitive Insights

Companies that dominate excipient market are Avantor Performance Materials, P&G, Huntsman Corporation, Eastman Chemical Company, BASF, Ashland Inc., Danisco A/S, FMC Corporation, Lubrizol Corporation, and Evonik Industries.

There is a high industry rivalry with intense competition. By capitalizing the untapped market and other strategies such as mergers & acquisitions, integration and collaborations of R&D for better outcomes the companies aim to acquire higher market share.

See More Reports of this Category by Million Insights @ https://www.millioninsights.com/industry/pharmaceuticals

Empty Capsules Market Categorization, Product Estimates & Trend Analysis 2024

4 Oct 2018 - The Global Empty Capsules Market was estimated at USD 1.34 billion in 2015 and is expected to grow at a CAGR of 6.6% over the forecast period. The major factors impelling the market growth are increasing adoption rate of capsules when compared to tablets, rising demand of empty capsules in cosmeceutical, nutraceutical and pharmaceutical industries and growing geriatric population. Capsule- based formulations are more popular among the aged population, owing to benefits like faster dissolution time as compared to the other oral dosage forms, capsules make swallowing easier for patients, moreover, the gastrointestinal irritation caused by capsules is comparatively less than other dosage forms. These aforementioned benefits associated with capsules are likely to boost the market growth over the forecast period.

However, the religious and cultural issues arising due to use of animal derivatives, such as bovine and porcine gelatin capsules and growing prices of raw materials, are expected to hinder the market growth over the forecast period.

Product Insights

According to the product type, empty capsules market is categorized into non-gelatin and gelatin capsules. In 2015, the gelatin capsules segment accounted for the largest market share and is anticipated to maintain its dominant position over the forecast period owing to the increase in use of gelatin capsules for formulating novel drug delivery systems and easy availability of gelatin for manufacturing purpose.

However, non-gelatin segment is expected to experience a comparatively faster growth at a CAGR of 6.89% over the forecast period. Major factors contributing to the growth of this segment include the strict government regulations for use of animal-derived gelatin, incompatibilities of certain drugs with gelatin capsules and better stability of non-gelatin capsules, which is expected to increase the demand for non-gelatin capsules.

Request Sample Copy of this Market Research @                      https://www.millioninsights.com/industry-reports/empty-capsules-market/request-sample

Therapeutic Application Insights

Major therapeutic application of empty capsules can be segmented into cold and cough preparations, anti-anemic preparations, anti-flatulent and antacid preparations, dietary and vitamin supplements, cardiac therapy drugs, anti-rheumatic and anti-inflammatory drugs, anti-bacterial and antibiotic drugs, and other therapeutic applications.

In 2015, antibacterial and antibiotic drugs segment accounted for the largest market share owing to the high prevalence of various chronic conditions and infectious diseases that are expected to impose high pressure on the pharmaceutical industries and consequently boost the empty capsule market over the forecast period.

End - use Insights

Based on end-use, the empty capsules market is segmented into research laboratories, cosmetic industry, nutraceutical industry and pharmaceutical industry.

Pharmaceutical industry segment generated the maximum revenue in 2015 and is expected to dominate the market throughout the forecast period, because of large scale use of capsules over other oral dosage forms, which is expected to promote demand of empty capsules in the pharmaceutical industry in order to treat various infectious and cardiac diseases.

Browse Full Research Report @                                                      https://www.millioninsights.com/industry-reports/empty-capsules-market

Regional Insights

North America’s accounted for highest share of the total empty capsules market in 2015 and is expected to grow at a CAGR of 6.1% during the forecast period owing to the high penetration rate of cosmeceutical and nutraceutical industry along with rising awareness of nutraceutical products among the consumers.

Asia-Pacific is expected to witness the fastest growth over the forecast period. This growth can be attributed to the increase in proliferation of pharmaceutical industry, rising awareness regarding cosmeceuticals and nutraceuticals products, improved healthcare infrastructure, and less stringent government regulations in the nutraceutical industry.

  
Competitive Insights
Some players in the empty capsules market include Sunil Healthcare Ltd. (Sunloc Healthcare, Inc.), Roxlor LLC, Patheon, Inc. (Banner Pharmacaps, Inc.), Qualicaps, Inc. (Mitsubishi Chemical Holdings Corporation), Medicaps Ltd., CapsCanada Corporation, JC Biological Technology Co. Ltd, ACG Associated capsules Pvt. Ltd., and Capsugel, Inc.

See More Reports of this Category by Million Insights @ https://www.millioninsights.com/industry/pharmaceuticals